MRC Centre for Transplantation

Lead Research Organisation: King's College London
Department Name: Transplantation Immunology & Mucosal Bio

Abstract

Organ transplantation has saved the lives of many thousands of people, but transplants still don't last as long as they should. In addition, to prevent rejection, high doses of toxic drugs are used to dampen the immune response. These can not only harm the transplant, but can have lethal side effects on the recipient.

Since it started in October 2007, the Centre has made significant progress towards improving the health of people who need transplants. We have devised ways to make their transplanted organ survive longer. This includes the development of engineered proteins which, when planted in donor kidneys, reduce inflammation and blood clot formation after transplantation. In addition, we have pioneered less harmful, more natural methods to coax the immune system into accepting the transplant, using cells taken from the patient. Remarkably, as a result of monitoring the immune system, we are close to being able to judge which patients can stop taking conventional therapy without rejecting the graft. At the same time, we are developing advanced scanning techniques that will enable physicians to diagnose whether a transplant is inflamed and to offer appropriate treatment.

As we approach the next five years of development, we shall conduct clinical trials to establish whether these innovations can benefit healthcare as the basic research has promised. Potential benefits include extending the life of the transplant and offering transplantation to more of those in need. We are also supporting new branches of science that make success more likely.

Advances of this complexity are made possible by bringing together a large workforce of scientists, clinicians and technologists under the same roof. The MRC Centre for Transplantation has created this capability within the UK. It collaborates with the Centre for Medical Law and Ethics at King's College to ensure a high standard of communication and public engagement regarding the regulation and ethics of transplant research. A programme of special events and media coverage will help keep the public and patients informed during innovation. Health economists are also to be part of the Centre to provide the opportunity to make more accurate forecasts about the costs and potential benefits of our research.

Future success will depend on recruiting and training the brightest minds to deliver this work through the next 5-10 years of development and ensure the research is translated into social and economic benefit.

Technical Summary

In 2007, the Centre set out to convert its extensive knowledge of inflammation, immunity and tolerance into new treatment, diagnostic and prognostic technologies for the benefit of patients. Our priorities were to overcome the initial barriers to transplantation presented by the immune system and to induce tolerance in patients with guidance from immune prediction and monitoring, so reducing some of the major limitations of modern transplantation.

To do this, we created links with protein and cell therapeutics, imaging sciences and genetics, and between clinical specialities responsible for the treatment of patients with diabetes, liver, kidney, bone marrow and dental diseases. As a result, the first membrane-targeted therapeutic regulators are about to enter a multicentre efficacy trial; the cell therapy strategy has progressed to become part of several investigational protocols designed to induce tolerance; markers of tolerance are undergoing extensive evaluation in man; and new imaging ligands that detect activated complement fragments and migratory T cells have emerged. A teaching framework built around these goals is equipping trainees to engage in multidisciplinary research. A programme of patient and public involvement promotes awareness of the importance of science in transplant medicine and ensures we are responsive to their expectations.

Our plan is to regroup the expanded number of basic and clinical research programmes into fewer themes which reflect areas of strategic value. This includes islet and hepatocyte transplantation, where inadequate long-term outcomes are likely to benefit from the specific expertise of the Centre. In support, an expanded training scheme will develop leadership skills in the distinct areas defined by the new themes, i.e. protein and cell engineering, immune monitoring, imaging and informatics. A parallel theme to improve methods of health economic assessment for early research is designed to support these goals.

Planned Impact

Benefit to patients
Improved quality of life, graft and patient survival rates, fewer interventions including less use of drug and dialysis treatment:
- Painting the donor organ with protective treatment that reduces inflammation and increases the lifespan of the transplant
- Having to take fewer drugs with unpleasant or dangerous side effects achieved with regimens using cell therapies in place of conventional treatment with broad-acting drugs
- Better patient stratification with new biomarkers and immune monitoring, allowing reduced drug usage where immune tolerance has developed
- Shorter wait for a kidney transplant through more donor organs being available with the application of organ-painting
- Evidence should be visible within 5-10 years

Benefits to the NHS
Cost/resource/efficiency benefits gained through costs of treatment (drug and dialysis costs) and patient and graft outcomes:
- Lower dialysis costs by enabling more transplants to be carried out with the use of organ painting and by fewer patients having to return to dialysis after transplantation
- Lower cost of dialysis in the early post transplant period due to more rapid recovery of painted donor organs
- Lower maintenance drug costs by keeping patients on fewer drugs where immune tolerance can be detected and/or can be induced by cell therapy
- Increased patient and graft survival rates with wider application of these treatment and diagnostic technologies, within 10 years

Benefits to the Economy
Exploitation of IP to form new products which contribute to UK economy and allow return on public investment in the work of the MRC Centre/KCL, by:
- New intellectual property based around these therapeutic and biomarker technologies (interest already showing in new cytotopic products and biomarkers of tolerance)
- Healthcare savings since maintenance on a transplant is more cost-effective than dialysis.

Benefits to Wider Society
Engagement/participation, leading to:
- Public confidence in organ donation, building on our ability to engage the public and influence policy on matters that include research in transplantation
- Influence willingness to participate in organ donations schemes by appreciating the scientific commitment though research

Organisations

Publications


10 25 50
&NA; (2013) Anonymity and Live-Donor Transplantation in Transplantation Journal
Abboudi H (2013) Ureteric injury: a challenging condition to diagnose and manage. in Nature reviews. Urology
Adams DH (2015) From immunosuppression to tolerance. in Journal of hepatology
 
Title 3D prostates 
Description 3D printed prostates 
Type Of Art Image 
Year Produced 2015 
Impact Developed in collaboration with Nuada Medical for patient counselling and surgical planning during robotic procedures 
 
Title Translucent 
Description Tablet guided surgery 
Type Of Art Image 
Year Produced 2014 
Impact Developed a tablet based tool and performed the first in man for surgical navigation in UK and Italy. Demonstrated at the World Robotic Surgery Event with KCL being the only selected University from UK amongst 12 globally 
 
Description Appointed expert member of clinical and ethics/legal sub-group, and author of report. Presentation of findings at the Royal College of Paedicatric Child Health and Department of Health
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact If the Department of Health adopts the recommended changes this will impact on efficiency of healthcare delivery, it will facilitate research and it is anticipted it will improve survival and quality of life ofDCD transplantrecipients.
 
Description CORAL and subsequent Cochrane review on robotic cystectomy
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact -
 
Description Citation in subsequent frameowrk document
Geographic Reach National 
Policy Influence Type Citation in other policy documents
Impact Changed the arrangements for distribution for research purposes of organs retrieved but not transplanted
 
Description Expert reviewer and collaborator
Geographic Reach National 
Policy Influence Type Citation in other policy documents
 
Description House of Lords Regenerative Medicine Report (3 Centre PIs gave independent evidence)
Geographic Reach National 
Policy Influence Type Gave evidence to a government review
 
Description Influence on TTS policy on China
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in advisory committee
 
Description Invited to small working group at the Human Tissue Authority- in view of publications writtenon the subject and published in high impact factor ethics/law journals
Geographic Reach National 
Policy Influence Type Participation in advisory committee
 
Description Policy Document to guide clinical practice
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact .
 
Description Scientific Advisory Board, DIREKT EC Framework Programme
Geographic Reach Asia 
Policy Influence Type Participation in advisory committee
 
Description Technology Strategy Board Assessor Briefing for Healthcare
Geographic Reach National 
Policy Influence Type Participation in advisory committee
 
Description The first international robotics training curriculum
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
Impact -
 
Description Allergy, Immunology and Transplantation Research
Amount $44,155 (USD)
Organisation National Institutes of Health (NIH) 
Department National Institute of Allergy and Infectious Diseases (NIAID)
Sector Public
Country United States of America
Start 02/2016 
 
Description Allergy, Immunology, and Transplantation Research
Amount $25,920 (USD)
Organisation National Institutes of Health (NIH) 
Department National Institute of Allergy and Infectious Diseases (NIAID)
Sector Public
Country United States of America
Start 07/2016 
 
Description Capital Bid
Amount £1,690,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 10/2012 
End 09/2015
 
Description Collectin-11 as a trigger of the innate immune response in renal transplantation
Amount £560,440 (GBP)
Funding ID MR/M01226311 
Organisation MRC-UK 
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 03/2015 
End 02/2018
 
Description Complement UK PhD studentships 2016
Amount £210,000 (GBP)
Organisation Alexion Pharmaceuticals 
Sector Private
Country United States of America
Start 10/2016 
End 09/2020
 
Description EME programme award (Co-applicant with M Robson)
Amount £1,168,806 (GBP)
Funding ID 13/94/10 
Organisation Medical Research Council (MRC) 
Department Efficacy and Mechanism Evaluation (EME) Programme
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 01/2015 
End 12/2018
 
Description Efficacy and Mechanism Evaluation (EME)
Amount £300,000 (GBP)
Funding ID 13/94/55 
Organisation University College London Hospitals Charity (UCLH) 
Department National Institute for Health Research (NIHR)
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 02/2015 
End 02/2019
 
Description Efficacy and Mechanism Evaluation (EME) Programme
Amount £1,241,563 (GBP)
Funding ID 13/94/10 
Organisation University College London Hospitals Charity (UCLH) 
Department National Institute for Health Research (NIHR)
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 05/2015 
End 04/2019
 
Description Establishing the optimising Transplant Survival Clinic
Amount £37,317 (GBP)
Organisation Guy's and St Thomas' NHS Foundation Trust 
Department Guy’s and St Thomas’ Kidney Patients' Association (GSTT KPA)
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2011 
End 03/2014
 
Description Fan Qu visit - CSC fellowship
Amount £20,000 (GBP)
Organisation University of Leeds 
Department China Scholarship Council
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 11/2014 
End 10/2015
 
Description Funding for 4-year PhD studentships (x2) from KCL
Amount £200,000 (GBP)
Funding ID MJKRAAR 
Organisation King's College London (KCL) 
Department School of Medicine KCL
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 10/2013 
End 09/2017
 
Description Immune Tolerance Network
Amount $100,157 (USD)
Organisation National Institutes of Health (NIH) 
Department National Institute of Allergy and Infectious Diseases (NIAID)
Sector Public
Country United States of America
Start 02/2016 
 
Description Immune Tolerance Network
Amount $30,000 (USD)
Organisation National Institutes of Health (NIH) 
Department National Institute of Allergy and Infectious Diseases (NIAID)
Sector Public
Country United States of America
Start 02/2017 
End 01/2018
 
Description Impact Grant King's Policy Institute
Amount £20,000 (GBP)
Funding ID MJK9408 
Organisation King's College London (KCL) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 03/2013 
End 12/2014
 
Description Intermediate Clinical Fellowship - Dr Nicholas Powell
Amount £876,303 (GBP)
Funding ID 101159/Z/13/Z 
Organisation The Wellcome Trust Ltd 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2014 
End 09/2018
 
Description Investigator Driven Clinical Study Astellas
Amount £76,000 (GBP)
Organisation Astellas Pharma 
Sector Private
Country Japan
Start 10/2014 
End 10/2015
 
Description KHP Challenge Fund
Amount £73,882 (GBP)
Funding ID R140807 
Organisation King’s Health Partners 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2014 
End 09/2015
 
Description KHP R&D Challenge Fund
Amount £96,708 (GBP)
Funding ID R1405170 
Organisation Guy’s & St Thomas’ Charity 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 10/2014 
End 09/2015
 
Description KHP Research Grant
Amount £91,000 (GBP)
Organisation King’s Health Partners 
Department King's Health Partners Research and Development Challenge Fund
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 11/2013 
End 10/2014
 
Description KRUK Clinical Training Fellowship to Dr Philippa Dodd
Amount £258,741 (GBP)
Organisation Kidney Research UK 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2014 
End 08/2017
 
Description Kidney Research UK - M Robson
Amount £199,867 (GBP)
Funding ID RP1/2015 
Organisation Kidney Research UK 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 05/2016 
End 11/2018
 
Description Kidney Research UK Research Training Fellowship - Dr Philippa Dodd
Amount £258,741 (GBP)
Funding ID TF1/2014 
Organisation Kidney Research UK 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2014 
End 09/2017
 
Description King's Health Accelerator Award
Amount £130,213 (GBP)
Organisation King's College London (KCL) 
Department King's Commercialisation Institute
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 08/2016 
End 07/2017
 
Description King's Worldwide Partnership Fund
Amount £1,984 (GBP)
Organisation King's College London (KCL) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 03/2016 
End 04/2016
 
Description MRC Centenary Award 2013
Amount £30,000 (GBP)
Funding ID PO Number 4050246766 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 12/2012 
End 06/2013
 
Description MRC Centenary Award for early career researchers
Amount £45,000 (GBP)
Funding ID MR/J006742/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 10/2012 
End 12/2012
 
Description MRC Centre Directors Capital Bid 2013: CEL (Cell Engineering Laboratory)
Amount £203,000 (GBP)
Funding ID MR/J006742/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 10/2013 
End 03/2015
 
Description MRC Clinical Training Fellowship for Dr Hannah Burton
Amount £244,237 (GBP)
Funding ID MR/M01813X/1 
Organisation MRC-UK 
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2015 
End 08/2018
 
Description MRC Clinical Training Fellowship for Dr Harriot Doiuthwaite
Amount £223,234 (GBP)
Organisation MRC-UK 
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 10/2016 
End 10/2019
 
Description MRC DPFS
Amount £1,007,574 (GBP)
Funding ID MR/N019334/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 06/2017 
End 05/2021
 
Description MRC Fellowship
Amount £947,966 (GBP)
Funding ID G0902288 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 10/2010 
End 09/2014
 
Description MRC Project Grant
Amount £500,000 (GBP)
Funding ID MR/M012263/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 01/2015 
End 12/2018
 
Description MRC project Grant (Co-applicant with G. Lombardi)
Amount £483,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 02/2013 
End 01/2016
 
Description Marato TV3 Foundation
Amount € 324,500 (EUR)
Organisation La Marató de TV3 Foundation 
Sector Charity/Non Profit
Country Spain, Kingdom of
Start 10/2013 
End 10/2016
 
Description MiR-acles in collecting ducts underlie albuminuria-induced renal fibrosis
Amount £200,000 (GBP)
Organisation Kidney Research UK 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 12/2014 
End 11/2017
 
Description NIH research award
Amount $308,873 (USD)
Funding ID 5U01AI100807-03 
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States of America
Start 01/2015 
End 06/2017
 
Description NIHR BRC Bridging Fellowship - Dr Niloufar Safinia
Amount £66,989 (GBP)
Organisation University College London Hospitals Charity (UCLH) 
Department National Institute for Health Research (NIHR)
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 10/2014 
End 09/2015
 
Description NIHR EME
Amount £1,241,563 (GBP)
Funding ID 13/94/10 
Organisation National Institute for Health Research (NIHR) 
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 05/2015 
End 05/2019
 
Description NIHR HS&DR (Health Services and Delivery Research)
Amount £876,000 (GBP)
Organisation University College London Hospitals Charity (UCLH) 
Department National Institute for Health Research (NIHR)
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 02/2015 
End 01/2020
 
Description National Institute of Health Research Efficacy and Mechanism Evaluation (EME) Programme
Amount £1,677,143 (GBP)
Funding ID 13/94/55 
Organisation University College London Hospitals Charity (UCLH) 
Department National Institute for Health Research (NIHR)
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 01/2015 
End 11/2020
 
Description Pilot funding for retinoid dietary intervention in ADPKD mice
Amount £2,000 (GBP)
Funding ID N/A 
Organisation PKD Charity 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 04/2013 
End 06/2014
 
Description Project Grant Application - Targeting C5aR in chronic inflammation, renal fibrosis and late graft dysfunction
Amount £464,744 (GBP)
Funding ID MR/L020254/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 05/2014 
End 04/2017
 
Description Prostate Cancer Research Centre King's College London
Amount £1,500,000 (GBP)
Organisation Prostate Cancer Research Charity 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2014 
 
Description Quality in Organ Donation (QUOD)
Amount £60,608 (GBP)
Funding ID QUOD Centre 
Organisation NHS Blood and Transplant (NHSBT) 
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 01/2012 
End 12/2016
 
Description ROTRF
Amount £202,047 (GBP)
Organisation Roche Organ Transplantation Research Foundation (ROTRF) 
Sector Charity/Non Profit
Country Switzerland, Swiss Confederation
Start 10/2014 
End 09/2016
 
Description Roche Organ Transplantation Research Foundation
Amount £200,000 (GBP)
Funding ID 560883191 ROTRF 
Organisation Roche Organ Transplantation Research Foundation (ROTRF) 
Sector Charity/Non Profit
Country Switzerland, Swiss Confederation
Start 10/2014 
End 09/2016
 
Description Single Cell-Level Functional Proteomics and Genomics exemplified in Cancer and Immunology
Amount £2,386,712 (GBP)
Organisation MRC-UK 
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 07/2015 
End 06/2018
 
Description UK Regenerative Medicine Platform (UKRMP) - Research Hub (Prof Lombardi)
Amount £310,822 (GBP)
Funding ID MR/L022699/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2014 
End 08/2017
 
Description UK Regenerative Medicine Platform (UKRMP) - Research Hub (Prof Steve Sacks)
Amount £295,551 (GBP)
Funding ID MR/L022699/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2014 
End 08/2017
 
Description UK-AIH
Amount £10,000 (GBP)
Organisation National Institute for Health Research (NIHR) 
Department NIHR/BRC
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 12/2016 
End 12/2018
 
Description Wellcome Trust New Investigator Award (Dr Claudia Kemper)
Amount £1,519,891 (GBP)
Funding ID 102932/Z/13/Z 
Organisation The Wellcome Trust Ltd 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 04/2014 
End 03/2019
 
Description Wellcome Trust Translation Award (Co-applicant with Richard Smith)
Amount £1,300,000 (GBP)
Organisation The Wellcome Trust Ltd 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 01/2012 
End 12/2015
 
Title Elispot Standardisation 
Description Measures number of cytokine-producing cells after stimulation in vitro 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact Standarization of method that will be used to stratify kidney transplant recipients if the trial is positive 
URL http://www.biodrim.eu/description.html
 
Title GAMBIT cell and mRNA collection 
Description cells mRNA from blood serum urine mRNA fresh urine 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact Future biomarkers of tolerance to be developed 
 
Title GFP-C3 mouse 
Description Mouse engineered to express fluorescein-labelled complement protein (C3) that can be tracked in vivo. 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Provided To Others? No  
Impact The mouse has only just been generated. 
 
Title Humanised mouse model 
Description Immunodeficient mice reconstituted with human blood to study human immune responses in vivo and develop strategies to interfere with them. 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Provided To Others? No  
Impact Publications and future collaborations. 
 
Title Immunotoxin to prolong graft survival 
Description An immunotoxin that kills donor passenger leukocytes can induce indefinite survial of donor allografts 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2016 
Provided To Others? Yes  
Impact This can be adopted in the clinic to prolong graft survival in humans. 
 
Title Indices of Tolerance Array 
Description Data on mRNA array 
Type Of Material Database/Collection of Data/Biological Samples 
Year Produced 2010 
Provided To Others? Yes  
Impact Access by other researchers PMID: 21827613 
URL http://GSO.htm
 
Title KALIBRE mRNA and cell collection 
Description PBMC stored in liquid nitrogen mRNA from blood plasma fresh urine - frozen - mRNA extracted from urine 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact Not yet 
 
Title Phospholipid Capture Enzyme Immunoassay (PCEIA) 
Description The PCEIA is a generic system for the assay of cytotopic agents (CTAs). CTAs are modified protein or peptides which possess the ability to bind to phosphatidyl serine (PS) and related acidic phospholipids in cell membranes. The assay uses PS deposited on the wells of microtitre plates as the capture step. The protein or peptide component of the CTA is then detected with a specific antibody followed by a secondary antibody linked to an enzyme component such as horseradish peroxidase. The signal is detected colorimetrically with an appropriate enzyme substrate. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact A PCEIA for the complement inhibitor Mirococept was initially developed in response to a regulatory requirement (from the UK MHRA) for an additional potency assay for this agent. It was reasoned that an assay which was dependent not only on the ability to bind PS but also on the antigenic identity of the CTA would be complementary to the existing biological assay for complement inhibitors which is cell-based. This proved to be the case and the new assay was incorporated into a revised MIrococept Investigational Medicinal Product Dossier (IMPD) filed in late 2013. We realized that the same capture step could be applied to all CTAs regardless of the modified "cargo". During 2014 we have validated this approach for the anticoagulant Thrombolexin and the complement terminal pathway inhibitor Cytectin. This work has been written up for publication and we expect it to contribute not only to the development of a range of CTAs but also to ultimate commercialization 
 
Title Refinement of heart transplant technique 
Description A new less traumatic method to perform heart transplant in mice 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2015 
Provided To Others? Yes  
Impact It is now published, others using the technique can easily learn it with the help of an on line video 
 
Title anti-human and mouse VISTA monoclonal antibidies 
Description antibodies specific to human and mouse VISTA 
Type Of Material Antibody 
Year Produced 2011 
Provided To Others? Yes  
Impact new target for immnotherapy 
 
Title laparoscopic renal transplantation 
Description an animal model for laparoscopic renal transplantation, a novel clinical technique, which has involved collaboration with Prof Campistol in Barcelona, and with the surgical department at St Georges hospital. The model is being refined with a view to translation to human subjects later this year. 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Provided To Others? No  
Impact The model is being refined with a view to translation to human subjects later this year. 
 
Title British Association of Urological Surgeons, 
Description National Publicly available database 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact First such national data on cancer patients 
URL http://www.baus.org.uk/
 
Title Liver Tolerance Database 
Description Database containing sequential liver histology from liver transplant recipients enrolled in immunosuppression withdrawal trials. 
Type Of Material Database/Collection of data 
Year Produced 2014 
Provided To Others? Yes  
Impact - Identification of transient inflammatory changes in the liver allografts of patients undergoing successful immunosuppression withdrawal. - Has allowed us define the acceptable inclusion/exclusion criteria for future immunosuppression withdrawal trials. 
 
Title NHR-HIC 
Description Integration of anonymised clinical data and "omics" for research and clinical purposes 
Type Of Material Data handling & control 
Year Produced 2015 
Provided To Others? Yes  
Impact No impact yet. 4 collaborating groups: Cambridge, Oxford, Imperial and KCL. It will be expanded UK-wide within 3 - 5 years It will facilitate research and clinical practice in a large scale 
URL http://www.nihr.ac.uk/about/hic.htm
 
Description Alexion Pharmaceuticals 
Organisation Alexion Pharmaceuticals
Country United States of America 
Sector Private 
PI Contribution We collaborated on an investigator led pre clinical study to determine the impact of complement inhibitor (anti-C5) on reperfusion injury in native and transplant kidneys.
Collaborator Contribution Alexion Pharmaveuticals provided Chemicals, Consumables and animals to this study
Impact The therapeutic antibody failed to penetrate into transplanted kidney and therefore helped to define types of injury that would not amenable to this particular therapeutic strategy.
 
Description Anti inflammatory and anti thrombin - Duke University 
Organisation Duke University
Country United States of America 
Sector Academic/University 
PI Contribution What the link embraces 1. Distinctive areas of strength that complement the academic plans at both Centres 2. Added value to the training of future clinical-academic leaders A cross-centre training programme based on a critical set of scientific questions and skills 3. Enhanced metrics for training in health services research 4. Benefits of cross-centre evaluation of clinical-academic programmes 5. Leveraging funding to support the proposed activities and goals
Collaborator Contribution Research training and consumables including non human primates.
Impact Abstract at the American Society for Transplantation
Start Year 2015
 
Description Antibody Incompatible Transplantation 
Organisation Guy's and St Thomas' NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Nizam Mamode set up and is Clinical Lead for the Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK. As well as reporting outcome data, I am interested in the effect of B cell depletion on T cell responses in blood group incompatible transplant patients. This project was carried out at Guys but has involved collaboration with a national study of blood group incompatible patients (the ABOUT-K study run by Dr Simon Ball in Birmingham).
Collaborator Contribution The Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK.
Impact The Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK.
Start Year 2012
 
Description Antibody Incompatible Transplantation 
Organisation University Hospitals Birmingham NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Nizam Mamode set up and is Clinical Lead for the Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK. As well as reporting outcome data, I am interested in the effect of B cell depletion on T cell responses in blood group incompatible transplant patients. This project was carried out at Guys but has involved collaboration with a national study of blood group incompatible patients (the ABOUT-K study run by Dr Simon Ball in Birmingham).
Collaborator Contribution The Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK.
Impact The Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK.
Start Year 2012
 
Description Apellis (Louisville, USA) 
Organisation Apellis Pharmaceutical
Country United States of America 
Sector Private 
PI Contribution Experiments on the role of C5L2 in T cell responses in in vivo disease models.
Collaborator Contribution Generation and provision of human C5L2 targeted reagents (agonists and antagonists).
Impact Patent application pending
Start Year 2012
 
Description Assessing the role of complement-mediated regulation of Th1 responses in health and disease 
Organisation Guy's and St Thomas' NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution We have discovered one of the molecular pathways controlling IFN-gamma ; 'shut down' in Th1 cells and the corresponding defect in RA patients T cells. We are now assessing this pathway in detail - as the 'basic science team' - and keep collaborating with the clinical team to asses if identified deregulation points can be predicted or corrected therapeutically in RA patients.
Collaborator Contribution We have partnered with several clinicians working on rheumatoid arthritis (RA) at Guy's hospital. In addition, we are now included in an ongoing clinical trial at Guy's Hospital assessing factors that help predicting if and when RA patients can be 'weaned off' anti-TNF therapy.
Impact "Grant money: 2011-2018. IMI (Innovative Medicine Initiative - FP7/2009) by the European Union. Understanding aberrant adaptive immunity mechanisms in human chronic immune-mediated diseases: rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease. Application package jointly submitted by 14 European Research Institutions and 11 Biotechnology companies. Coordinating Director: Prof. Dr. T.W.J. Huizinga, Leiden University, Netherlands. €6.5 Mio. KingÂ' College portion: £680.000 Role: Leading Scientist (KingÂ's College Stream; Lead-PI: Andy Cope) 2011-2014 MRC Project Grant. The molecular and cellular basis of complement-mediated T helper 1 (Th1) differentiation and regulation. Kemper C, Cope A, Rebello-Mesa I and Lavender P. £860.000 Role: PI Peer reviewed publications: 1.Cardone, J, Le Friec, G, Vantourout, P, Roberts, A, Fuchs, A, Jackson, I, Suddason, T, Lord, G, Atkinson, JP, Cope, A, Hayday, A and Kemper, C. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol 2010. 11(9):862-871. 2. Cope, A, Le Friec, G, Cardone, C and Kemper, C. The lifecycle of Th1 cells: molecular control of IFN-γ to IL-10 switching. TRENDS Immunol 2011. 32:278-286. 3. Cardone, C, Le Friec, G, and Kemper, C. CD46 in innate and adaptive immunity: An update. Clin Exp Immunol 2011. 164:301-311. 4. Heeger, P, and Kemper, C. Novel roles of complement in T effector cell regulation. Immunobiology. 2011. doi:10.1016/j.imbio.2011.06.004 Conference presentations/invited lectures: Immunology Seminar Series, Oxford University, Dunn School of Pathology; Complement and T cell homeostasis. 2010 Â'John Humphrey Seminar SeriesÂ' at Imperial College, London, UK; Complement: Tipping the balance between successful host defense and autoimmunity. 2010 Regional BSI group seminar series Cardiff University, UK; Complement during T cell activation: Timing (and the microenvironment) is key. 2010 BSI Annual Conference, Liverpool, UK; Complement, T cells and autoimmunity. 2011 Immunology Seminar Series, Cambridge University; Innate signals regulating Th1 immunity. 2011 Wright-Fleming Institute Seminar Series, Imperial College London; Towards a molecular Th1 life cycle signature. 2011 UCB, Slough, UK. Therapeutic interventions in Th1-mediated autoimmune disease states. 2011 8th International Conference on Innate Immunity, Chania, Greece: Innate immune signals in the regulation of Th1 responses. 2011 Annual BSI Â'Showcase of ImmunologyÂ', London, UK; CD46: Just a Notch up your common complement regulator."
Start Year 2010
 
Description BIO-DRIM FP7 EU Consortium 
Organisation Charité - University of Medicine Berlin
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution We are the lead investigators in a multi-national clinical trial of immunosuppression discontinuation in liver transplantation. The trial involves clinical sites in UK, Germany, Belgium and Spain, and is funded in part by the EU FP7 BIO-DRIM Consortium.
Collaborator Contribution Support on quality of life and health-economic analyses. Support on biomarker commercialisation strategy.
Impact No outputs yet.
Start Year 2013
 
Description BIO-DrIM. FP7 - Consortium 
Organisation ALTA
Department Research and Development in Biotechnology
Country Italy, Italian Republic 
Sector Private 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation Astellas Pharma
Country Japan 
Sector Private 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation Bristol-Myers Squibb
Country United States of America 
Sector Private 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation Catalan Health Institute (ICS)
Department University Hospital of Bellvitge (HUB)
Country Spain, Kingdom of 
Sector Hospitals 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation Cellogic GmbH
Country Germany, Federal Republic of 
Sector Private 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation Charité - University of Medicine Berlin
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation Genome Identification Diagnostics GmbH
Country Germany, Federal Republic of 
Sector Private 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation Immunotech S.A.S.
Country France, French Republic 
Sector Private 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation Institute for Clinical and Experimental Medicine (IKEM)
Country Czech Republic 
Sector Academic/University 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation King's College London (KCL)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation Milenia Biotec GmbH
Country Germany, Federal Republic of 
Sector Private 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation University Hospital of Nantes
Country France, French Republic 
Sector Hospitals 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation University of Amsterdam
Country Netherlands, Kingdom of the 
Sector Academic/University 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation University of Hamburg
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation University of Oxford
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description BIO-DrIM. FP7 - Consortium 
Organisation University of Regensburg
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation. King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL. STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects. STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard post-transplant follow up. The experimental arm will have a "Biomarker-led" follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS weaning to positive patients. WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.
Collaborator Contribution The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes 5 innovative investigator-driven biomarker clinical trials designed by the consortium with >1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard IS in long-term stable liver and kidney Tx patients identified as "operationally tolerant" by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.
Impact None published yet
Start Year 2011
 
Description Brian Sutton- Crystal structure of VISTA 
Organisation King's College London (KCL)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution We provide recombinant VISTA proteins for structural studies
Collaborator Contribution They evaluate crystal structure of VISTA
Impact None
Start Year 2013
 
Description CL-11 Ligand characterization 
Organisation Imperial College London (ICL)
Department Imperial College of Science Technology and Medicine (ICSTM)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution We established the relationship on the basis of preliminary data on Collectin-11. We provided the research question in support of the successful grant application awarded by the MRC.
Collaborator Contribution Specialist knowledge concerning carbohydrate arrays enabling exploration of the Collectin-11 ligand on renal tissue.
Impact preliminary carbohydrate array work carried out and being further developed.
Start Year 2014
 
Description Cell therapy in liver transplant patients 
Organisation University of San Francisco (USF)
Country United States of America 
Sector Academic/University 
PI Contribution Comparison of cell therapy using two preparations of regulatory T cells in liver transplant patients with the same clinical therapy.
Collaborator Contribution Generation of antigen-specific Tregs using B cells as antigen presenting cells.
Impact 1 publication so far.
Start Year 2011
 
Description Chelsea Therapeutics 
Organisation Chelsea Therapeutics
Country United States of America 
Sector Private 
PI Contribution We have developed a biomarker for clinical trials.
Collaborator Contribution The company provided a drug compound (an anti-folate)
Impact We have published a paper, Pubmed ID: 18343249
Start Year 2007
 
Description Chemocentryx 
Organisation ChemoCentryx
Country United States of America 
Sector Private 
PI Contribution Testing a human complement inhibitor (C5a receptor anatgonist) in animal models.
Collaborator Contribution Donated the complement inhibitor and transgenic mice expressing the human target.
Impact Grant submitted to the MRC using pilot data generated by this partnership.
Start Year 2013
 
Description Collaboration with UCB 
Organisation UCB Pharma
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Formal consultancy arrangement with UCB concerning planning and delivery of a phase 2 clinical trial in renal transplant patients
Collaborator Contribution UCB will provide a novel drug for this investigator-led study
Impact none yet
Start Year 2016
 
Description Collectin 11 and lung inflammation with the University of Denver 
Organisation University of Colorado
Department University of Colorado (Denver)
Country United States of America 
Sector Academic/University 
PI Contribution Sent the breeding pairs of mice with deficiency of collectin 11 and telephone conference call set up.
Collaborator Contribution Expertise on the animal model of lung disease
Impact None so far
Start Year 2016
 
Description Collectin 11 at the front line of tissue response stress - Complement UK research studentship 
Organisation Alexion Pharmaceuticals
Country United States of America 
Sector Private 
PI Contribution Prepared PhD project proposal and being the primary supervisor of the PhD student
Collaborator Contribution Full PhD scholarship (4 years)
Impact Obtained a full PhD studentship (4 years)
Start Year 2013
 
Description Complement UK 
Organisation Cardiff University School of Medicine
Department Institute of Infection and Immunity
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation Central Manchester University Hospitals NHS Foundation Trust
Department Nephrology and Transplantation
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation College of Medicine, Biological Sciences and Psychology
Department Department of Biochemistry
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation Faculty of Medicine
Department Department of Medicine
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation Faculty of Science
Department Department of Biology and Biochemistry
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation Great North Children's Hospital (GNCH)
Department Pediatric Nephrology
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation Leeds Teaching Hospitals NHS Trust
Department Department of Clinical Haematology
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation Medical Research Council (MRC)
Department MRC Human Genetics Unit
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation Newcastle University
Department Institute of Cellular Medicine
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation Newcastle University
Department Institute of Human Genetics
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation School of Clinical Medicine
Department Department of Clinical Biochemistry
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation UCL School of Life and Medical Sciences
Department UCL Research Department of Epidemiology and Public Health
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation University College London (UCL)
Department Institute of Ophthalmology UCL
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation University College London (UCL)
Department UCL Institute of Neurology
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation University College London (UCL)
Department UCL Structural Molecular Biology
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation University of Bristol
Department School of Cellular and Molecular Medicine
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation University of Cambridge
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation University of East Anglia
Department School of Medicine UEA
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation University of Edinburgh
Department School of Biological Sciences Edinburgh
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation University of Edinburgh
Department School of Chemistry Edinburgh
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation University of Leicester
Department Department of Infection Inflammation and Immunity
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation University of Oxford
Department Sir William Dunn School of Pathology
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation University of Southampton
Department School of Medicine Southampton
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement UK 
Organisation University of Warwick
Department Warwick Medical School
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.
Collaborator Contribution The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.
Impact Alexion funded four year PhD Studentships x 4 First annual conference 2011; repeated 2012, 2013. Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)
Start Year 2009
 
Description Complement and Coagulation interaction in hyperacute rejection 
Organisation Imperial College London (ICL)
Department Faculty of Medicine
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Rat model of hyperacute rejection. Model for therapeutic intervention by treatement of the donor organ with membrane associated thrombin and complement regulators
Collaborator Contribution It has exposed new interactions between thrombin and complement regulators induced by antibody bidning and has identified a new therapeutic strategy for prevention of rejection
Impact Presentation of findings at international complement and transplant meetings. Potential new treatment strategy relevant to sentised transplant recipients. New IP registered for the membrane targeted antithrombin (PTL004 and PTL006).
Start Year 2008
 
Description Complement and Coagulation interaction in hyperacute rejection 
Organisation Medical Research Council (MRC)
Department MRC Centre for Transplantation
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Rat model of hyperacute rejection. Model for therapeutic intervention by treatement of the donor organ with membrane associated thrombin and complement regulators
Collaborator Contribution It has exposed new interactions between thrombin and complement regulators induced by antibody bidning and has identified a new therapeutic strategy for prevention of rejection
Impact Presentation of findings at international complement and transplant meetings. Potential new treatment strategy relevant to sentised transplant recipients. New IP registered for the membrane targeted antithrombin (PTL004 and PTL006).
Start Year 2008
 
Description Cost action BM1305. "Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies (A FACTT)" 
Organisation European Science Foundation (ESF)
Department European Cooperation in Science and Technology (COST)
Country European Union (EU) 
Sector Public 
PI Contribution ME and my team participate in 2 working subgroups "Flow Cytometry", "mRNA-QPCR analysis" and "Functional Analysis". Mainly in method harmonisation process
Collaborator Contribution Provide talks, information, SOPs and collaborating in writing a manuscript
Impact 1. Science Translational Medicine 09 Sep 2015: Vol. 7, Issue 304, pp. 304ps18 DOI: 10.1126/scitranslmed.aaa7721 2. 3 x Joint Management Committee (MC) and Working Groups (WG) Meetings have taken place in Newcastle (2014), Lisbon (2015) and Gdansk (2015)
Start Year 2013
 
Description Cost action in preparation. "Immuno modulation strategies to improve outcomes in transplanted children" 
Organisation Autonomous University of Madrid (Universidad Autónoma de Madrid UAM)
Department Hospital Universitario La Paz
Country Spain, Kingdom of 
Sector Hospitals 
PI Contribution Establishing objectives and partnership
Collaborator Contribution n/a
Impact n/a
Start Year 2016
 
Description Cytectin structural studies 
Organisation University of Oxford
Department Sir William Dunn School of Pathology
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Provided Cytectin
Collaborator Contribution Oxford University provided data on its structural interaction with membranes.
Impact Publication May 2013 Cell Reports Cell Rep. 2013 May 30;3(5):1369-77. doi: 10.1016/j.celrep.2013.04.029. Epub 2013 May 9. Structural basis for recognition of the pore-forming toxin intermedilysin by human complement receptor CD59. Johnson S, Brooks NJ, Smith RA, Lea SM, Bubeck D. PMID: 23665225 [PubMed - in process] PMCID: PMC3675674
Start Year 2013
 
Description EMPIRIKAL Consortium 
Organisation British Transplantation Society (BTS)
Department Clinical Trials Network
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution We have provided the underpinning science to the clinical trial (EMPIRIKAL) of a novel membrane associated complement regulator, have formulated the clinical protocol and have secured funding with the MRC DCS to enable the study.
Collaborator Contribution Planning of the protocol. Potential patient involvement.
Impact First investigator meeting held October 2012. Protocol modifications.
Start Year 2012
 
Description EMPIRIKAL Consortium 
Organisation University of Cambridge
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution We have provided the underpinning science to the clinical trial (EMPIRIKAL) of a novel membrane associated complement regulator, have formulated the clinical protocol and have secured funding with the MRC DCS to enable the study.
Collaborator Contribution Planning of the protocol. Potential patient involvement.
Impact First investigator meeting held October 2012. Protocol modifications.
Start Year 2012
 
Description EU Consortium 
Organisation University Hospital Regensburg
Country Germany, Federal Republic of 
Sector Hospitals 
PI Contribution Use of regulatory Tregs for the induction of tolerance in renal transplant patients
Collaborator Contribution Use of different cell type with the aim to induce tolerance in renal transplant patients
Impact Few manuscripts submitted.
Start Year 2010
 
Description Emory 
Organisation Emory University
Country United States of America 
Sector Academic/University 
PI Contribution Clinical fellows exchange programme adding value to joint research projects between Emory and KCL.
Collaborator Contribution What the link embraces 1. Distinctive areas of strength that complement the academic plans at both Centres 2. Added value to the training of future clinical-academic leaders A cross-centre training programme based on a critical set of scientific questions and skills 3. Enhanced metrics for training in health services research 4. Benefits of cross-centre evaluation of clinical-academic programmes 5. Leveraging funding to support the proposed activities and goals
Impact Dr Stuart Hurst, a medical trainee from Emory, started the collaborative programme by joining the MRC Centre for Transplantation for 2 years in July 2013, under Professors Anthony Dorling and Steven Sacks' supervision. Dr Blayne Sayed from Emory has joined the MRC Centre in July 2014 under the supervision of Professor Alberto Sanchez Fueyo. The MRC Centre for Transplantation awarded MRC Centre two Emory Bridging Fellowships and appointed two female surgical trainees to carry out research projects at Emory in the USA. Their sabbaticals are due to start in 2015.
Start Year 2013
 
Description FP7 Consortium 
Organisation ALTA
Country Italy, Italian Republic 
Sector Private 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation Academic Medical Center (AMC)
Country Netherlands, Kingdom of the 
Sector Academic/University 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation Astellas Pharma
Country Japan 
Sector Private 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation Bristol-Myers Squibb
Country United States of America 
Sector Private 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation Catalan Health Institute (ICS)
Department University Hospital of Bellvitge (HUB)
Country Spain, Kingdom of 
Sector Hospitals 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation Cellogic GmbH
Country Germany, Federal Republic of 
Sector Private 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation Charité - University of Medicine Berlin
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation Genome Identification Diagnostics GmbH
Country Germany, Federal Republic of 
Sector Private 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation Immunotech S.A.S.
Country France, French Republic 
Sector Private 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation Institute for Clinical and Experimental Medicine (IKEM)
Country Czech Republic 
Sector Academic/University 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation King's College London (KCL)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation Milenia Biotec GmbH
Country Germany, Federal Republic of 
Sector Private 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation TcLand Expression
Country France, French Republic 
Sector Private 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation University Hospital of Nantes
Country France, French Republic 
Sector Hospitals 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation University of Hamburg
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation University of Oxford
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description FP7 Consortium 
Organisation University of Regensburg
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics
Impact FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance
Start Year 2011
 
Description GAMBIT Consortium 
Organisation Cardiff and Vale University Health Board (Bwrdd Iechyd Prifysgol Caerdydd a'r Fro)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation Central Manchester University Hospitals NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation East Kent Hospitals University NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation Great Ormond Street Hospital (GOSH)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation Guy's and St Thomas' NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation Hospital Universitari Vall d'Hebron
Country Spain, Kingdom of 
Sector Hospitals 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation Hull and East Yorkshire Hospitals NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation Institute for Clinical and Experimental Medicine (IKEM)
Country Czech Republic 
Sector Academic/University 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation King's College Hospital NHS Foundation Trust (NCH)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation Leeds Teaching Hospitals NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation NHS Greater Glasgow and Clyde (NHSGGC)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation Portsmouth Hospitals NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation Royal Free Hampstead NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation Salford Royal NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation Sheffield Teaching Hospitals NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation St George's Healthcare NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation University Hospitals of Leicester NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation University of Bern
Country Switzerland, Swiss Confederation 
Sector Academic/University 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT Consortium 
Organisation University of Uppsala
Country Sweden, Kingdom of 
Sector Academic/University 
PI Contribution I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.
Collaborator Contribution - Recruitment of eligible patients into a clinical study - Follow up and collection of samples from recruited patients - Provision of clinical data required for the study - Intellectual contribution to the study design.
Impact Congress communications: 1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. "A patient-centred approach to biomarkers of (transplant) tolerance". Bochum, Germany 2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA 3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA 4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin 6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin 8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin 9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303. 10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48. 11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA 12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord & M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 13. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA. 15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204 16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551 18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK 19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK 20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Naïve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK 21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561 Conferences: 1. July 2013. Rebollo Mesa I et al. "Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests". Birmingham. 2. May 2013, Uppsala University, Title: "Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning". Uppsala, Sweden 3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK 4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad clínica en transplante renal. Medellin, Colombia 6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland. 7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow 13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA 14. June, 2011, 17th N.A.T. Meeting (Nantes Actualités Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes 15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London 16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona 17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona 18. February, 2011, Joint Meeting Renal Association Société de Néphrologie. Title: Regulatory B cells in tolerant transplant patients. Paris 19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona 20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: "How to Measure Tolerance" 21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title "Indices de tolerancia Monitorizacion Inmunologica. 22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance. 23. July 6, 2010: Title: "Tolerogenic signatures; lessons from the transplant clinic". Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK. 24. June 3, 2010: Title: "RISET: consensus on tolerance markers in kidney transplantation". Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain. 25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation". Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 26. September 17, 2009. "Biomarkers of Tolerance in Kidney Transplantation" British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds Peer Review publications: NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year. PMID: 22797727 PMID: 22390816 PMID: 22219224 PMID: 22151236. PMID: 21749646 PMID: 21655296 PMID: 21909115 PMID: 21061447 PMID: 20659087 Review Articles in Journals PMID:23838646 PMID: 23574313 PMID: 23283248 KIDNEY INT Sup 2011; 1: 40-46. PMID: 20717098 (2010) TRENDS IN TRANSPLANT 4:68-67.
Start Year 2009
 
Description GAMBIT consortium 
Organisation Cardiff and Vale University Health Board (Bwrdd Iechyd Prifysgol Caerdydd a'r Fro)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Collaborator Contribution Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance
Impact Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Start Year 2010
 
Description GAMBIT consortium 
Organisation Central Manchester University Hospitals NHS Foundation Trust
Department Renal Care
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Collaborator Contribution Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance
Impact Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Start Year 2010
 
Description GAMBIT consortium 
Organisation East Kent Hospitals University NHS Foundation Trust
Department Renal Services East Kent Hospitals University
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Collaborator Contribution Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance
Impact Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Start Year 2010
 
Description GAMBIT consortium 
Organisation Great Ormond Street Hospital (GOSH)
Department Renal Department GOSH
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Collaborator Contribution Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance
Impact Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Start Year 2010
 
Description GAMBIT consortium 
Organisation Hull and East Yorkshire Hospitals NHS Trust
Department Renal Hull and East Yorkshire
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Collaborator Contribution Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance
Impact Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Start Year 2010
 
Description GAMBIT consortium 
Organisation King's College Hospital NHS Foundation Trust (NCH)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Collaborator Contribution Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance
Impact Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Start Year 2010
 
Description GAMBIT consortium 
Organisation Leeds Teaching Hospitals NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Collaborator Contribution Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance
Impact Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Start Year 2010
 
Description GAMBIT consortium 
Organisation Leicester General Hospital
Department Renal Unit
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Collaborator Contribution Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance
Impact Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Start Year 2010
 
Description GAMBIT consortium 
Organisation NHS Greater Glasgow and Clyde (NHSGGC)
Department Renal NHSGGC
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Collaborator Contribution Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance
Impact Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Start Year 2010
 
Description GAMBIT consortium 
Organisation Portsmouth Hospitals NHS Trust
Department Queen Alexandra Hospital
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Collaborator Contribution Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance
Impact Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Start Year 2010
 
Description GAMBIT consortium 
Organisation Royal Free Hampstead NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Collaborator Contribution Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance
Impact Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Start Year 2010
 
Description GAMBIT consortium 
Organisation Salford Royal NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Collaborator Contribution Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance
Impact Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Start Year 2010
 
Description GAMBIT consortium 
Organisation Sheffield Teaching Hospitals NHS Foundation Trust
Department Renal Unit Sheffield Teaching Hospitals
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Collaborator Contribution Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance
Impact Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Start Year 2010
 
Description GAMBIT consortium 
Organisation St George's Healthcare NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Collaborator Contribution Enabled the 3rd validation of biomarkers of Tolerance Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance
Impact Enabled the 3rd validation of biomarkers of tolerance Enabled the plan for a clinical Trial where Biomarkers will be tested
Start Year 2010
 
Description GP-TCM 
Organisation University of Mons
Country Belgium, Kingdom of 
Sector Academic/University 
PI Contribution I advised the research design and drafted part of the project and provided critical review and revision.
Collaborator Contribution Everyone brings in their perspectives and literature study outcomes in terms of integrated toxicological approaches to herbal medicines. I provided my perspectives as the PI of the GP-TCM project and as a nephrologist.
Impact his a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&flag=1&journal_id=sjzyyw&year_id=2015 (2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075 http://www.sciencemag.org/content/347/6219/337.3.summary (3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075 http://www.sciencemag.org/content/346/6216/1569.4.summary
Start Year 2007
 
Description Harvard University 
Organisation Harvard University
Department Harvard Medical School
Country United States of America 
Sector Academic/University 
PI Contribution We have built a research collaboration on biomarkers in transplantation with Professor Terry Strom, by giving him access to patients and testing his samples in the kidney transplant unit. We have jointly written grant awards (L. Barber and S. Longi) and we have jointly funded a joint postdoctoral researcher to look at tissue stress factors in transplantation. In addition, we have set up teaching sessions to introduce research opportunities from Harvard University and we have set up a major international symposium (GMEC Genetics Symposium, November 2009) which featured his work.
Collaborator Contribution We have access to confidential information and primer sequences that define potential biomarkers currently under investigation in our Centre as a result. It has facilitated recruitment of a new Professor to the MRC Centre from the USA.
Impact 1. Organising GMEC Genetics Symposium (2009) 2. Organising workshops 3. Putting in two grant applications 4. Partnership with Quest (negotiation stage)
Start Year 2007
 
Description Immune Tolerance Network 
Organisation Immune Tolerance Network
Country United States of America 
Sector Charity/Non Profit 
PI Contribution King's will act as the central laboratory for gene expression analysis of the I-WITH trial, a US multi-centre clinical trial of immunosuppression withdrawal in paediatric liver transplant recipients. We will be responsible for conducting PCR and microarray experiments as well as data analysis.
Collaborator Contribution Will provide funds and biological specimens to conduct the outlined experiments.
Impact No outputs yet.
Start Year 2012
 
Description Indices of Tolerance 
Organisation Charité - University of Medicine Berlin
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator. We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients
Collaborator Contribution Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did "the trans-vivo" DTH assay, etc ....
Impact JOURNAL ARTICLES: PMID: 20501946 PMID: 20501943 PMID: 20383145 PMID: 18633344 TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51 PMID: 17700166 PMID: 16082338 PMID: 17004249 Transplant Proc. 2007 Oct;39(8):2665-7 COMMUNICATIONS: Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005. A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007. POSTERS The Renal Association Annual Conference, May 2007, Brighton UK. "Indices of tolerance in kidney transplants" P103-PG05 American Transplant Congress May 2007, San Francisco USA. "Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients". American Transplant Congress May 2007, San Francisco USA. "Biomarkers of tolerance in kidney transplants". World Transplant Congress July 2006, Boston USA. "Advances in Immune Monitoring in Renal Transplantation". British Transplantation Society, March 2006, Edinburgh UK. "Indices of immunological tolerance". American Transplant Congress May 2007, San Francisco USA. "Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription". British Society of Immunology February 2007, Glasgow UK. "Tregs in peripheral blood of Clinically defined groups of renal transplant recipients" ORAL COMMUNICATIONS XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. "Indices of tolerance in kidney transplants." World Transplant Congress July 2006, Boston USA. "Indices of tolerance: Interim Report". 7th Trends in immunosuppression, February 2006 Berlin, Germany. "Fingerprinting tolerance in Renal Transplantation". Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21 American Transplant Congress May 2007. "Is it possible to tissue type a kidney donor who is no longer available?". 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. "T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection." Oral presentation by Patrick Miqueu.
 
Description Indices of Tolerance 
Organisation Immune Tolerance Network
Country United States of America 
Sector Charity/Non Profit 
PI Contribution King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator. We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients
Collaborator Contribution Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did "the trans-vivo" DTH assay, etc ....
Impact JOURNAL ARTICLES: PMID: 20501946 PMID: 20501943 PMID: 20383145 PMID: 18633344 TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51 PMID: 17700166 PMID: 16082338 PMID: 17004249 Transplant Proc. 2007 Oct;39(8):2665-7 COMMUNICATIONS: Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005. A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007. POSTERS The Renal Association Annual Conference, May 2007, Brighton UK. "Indices of tolerance in kidney transplants" P103-PG05 American Transplant Congress May 2007, San Francisco USA. "Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients". American Transplant Congress May 2007, San Francisco USA. "Biomarkers of tolerance in kidney transplants". World Transplant Congress July 2006, Boston USA. "Advances in Immune Monitoring in Renal Transplantation". British Transplantation Society, March 2006, Edinburgh UK. "Indices of immunological tolerance". American Transplant Congress May 2007, San Francisco USA. "Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription". British Society of Immunology February 2007, Glasgow UK. "Tregs in peripheral blood of Clinically defined groups of renal transplant recipients" ORAL COMMUNICATIONS XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. "Indices of tolerance in kidney transplants." World Transplant Congress July 2006, Boston USA. "Indices of tolerance: Interim Report". 7th Trends in immunosuppression, February 2006 Berlin, Germany. "Fingerprinting tolerance in Renal Transplantation". Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21 American Transplant Congress May 2007. "Is it possible to tissue type a kidney donor who is no longer available?". 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. "T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection." Oral presentation by Patrick Miqueu.
 
Description Indices of Tolerance 
Organisation Imperial College London (ICL)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator. We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients
Collaborator Contribution Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did "the trans-vivo" DTH assay, etc ....
Impact JOURNAL ARTICLES: PMID: 20501946 PMID: 20501943 PMID: 20383145 PMID: 18633344 TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51 PMID: 17700166 PMID: 16082338 PMID: 17004249 Transplant Proc. 2007 Oct;39(8):2665-7 COMMUNICATIONS: Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005. A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007. POSTERS The Renal Association Annual Conference, May 2007, Brighton UK. "Indices of tolerance in kidney transplants" P103-PG05 American Transplant Congress May 2007, San Francisco USA. "Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients". American Transplant Congress May 2007, San Francisco USA. "Biomarkers of tolerance in kidney transplants". World Transplant Congress July 2006, Boston USA. "Advances in Immune Monitoring in Renal Transplantation". British Transplantation Society, March 2006, Edinburgh UK. "Indices of immunological tolerance". American Transplant Congress May 2007, San Francisco USA. "Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription". British Society of Immunology February 2007, Glasgow UK. "Tregs in peripheral blood of Clinically defined groups of renal transplant recipients" ORAL COMMUNICATIONS XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. "Indices of tolerance in kidney transplants." World Transplant Congress July 2006, Boston USA. "Indices of tolerance: Interim Report". 7th Trends in immunosuppression, February 2006 Berlin, Germany. "Fingerprinting tolerance in Renal Transplantation". Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21 American Transplant Congress May 2007. "Is it possible to tissue type a kidney donor who is no longer available?". 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. "T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection." Oral presentation by Patrick Miqueu.
 
Description Indices of Tolerance 
Organisation Milenia Biotec GmbH
Country Germany, Federal Republic of 
Sector Private 
PI Contribution King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator. We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients
Collaborator Contribution Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did "the trans-vivo" DTH assay, etc ....
Impact JOURNAL ARTICLES: PMID: 20501946 PMID: 20501943 PMID: 20383145 PMID: 18633344 TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51 PMID: 17700166 PMID: 16082338 PMID: 17004249 Transplant Proc. 2007 Oct;39(8):2665-7 COMMUNICATIONS: Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005. A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007. POSTERS The Renal Association Annual Conference, May 2007, Brighton UK. "Indices of tolerance in kidney transplants" P103-PG05 American Transplant Congress May 2007, San Francisco USA. "Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients". American Transplant Congress May 2007, San Francisco USA. "Biomarkers of tolerance in kidney transplants". World Transplant Congress July 2006, Boston USA. "Advances in Immune Monitoring in Renal Transplantation". British Transplantation Society, March 2006, Edinburgh UK. "Indices of immunological tolerance". American Transplant Congress May 2007, San Francisco USA. "Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription". British Society of Immunology February 2007, Glasgow UK. "Tregs in peripheral blood of Clinically defined groups of renal transplant recipients" ORAL COMMUNICATIONS XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. "Indices of tolerance in kidney transplants." World Transplant Congress July 2006, Boston USA. "Indices of tolerance: Interim Report". 7th Trends in immunosuppression, February 2006 Berlin, Germany. "Fingerprinting tolerance in Renal Transplantation". Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21 American Transplant Congress May 2007. "Is it possible to tissue type a kidney donor who is no longer available?". 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. "T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection." Oral presentation by Patrick Miqueu.
 
Description Indices of Tolerance 
Organisation University Libre Bruxelles (Université Libre de Bruxelles ULB)
Country Belgium, Kingdom of 
Sector Academic/University 
PI Contribution King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator. We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients
Collaborator Contribution Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did "the trans-vivo" DTH assay, etc ....
Impact JOURNAL ARTICLES: PMID: 20501946 PMID: 20501943 PMID: 20383145 PMID: 18633344 TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51 PMID: 17700166 PMID: 16082338 PMID: 17004249 Transplant Proc. 2007 Oct;39(8):2665-7 COMMUNICATIONS: Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005. A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007. POSTERS The Renal Association Annual Conference, May 2007, Brighton UK. "Indices of tolerance in kidney transplants" P103-PG05 American Transplant Congress May 2007, San Francisco USA. "Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients". American Transplant Congress May 2007, San Francisco USA. "Biomarkers of tolerance in kidney transplants". World Transplant Congress July 2006, Boston USA. "Advances in Immune Monitoring in Renal Transplantation". British Transplantation Society, March 2006, Edinburgh UK. "Indices of immunological tolerance". American Transplant Congress May 2007, San Francisco USA. "Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription". British Society of Immunology February 2007, Glasgow UK. "Tregs in peripheral blood of Clinically defined groups of renal transplant recipients" ORAL COMMUNICATIONS XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. "Indices of tolerance in kidney transplants." World Transplant Congress July 2006, Boston USA. "Indices of tolerance: Interim Report". 7th Trends in immunosuppression, February 2006 Berlin, Germany. "Fingerprinting tolerance in Renal Transplantation". Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21 American Transplant Congress May 2007. "Is it possible to tissue type a kidney donor who is no longer available?". 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. "T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection." Oral presentation by Patrick Miqueu.
 
Description Indices of Tolerance 
Organisation University of Nantes
Country France, French Republic 
Sector Academic/University 
PI Contribution King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator. We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients
Collaborator Contribution Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did "the trans-vivo" DTH assay, etc ....
Impact JOURNAL ARTICLES: PMID: 20501946 PMID: 20501943 PMID: 20383145 PMID: 18633344 TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51 PMID: 17700166 PMID: 16082338 PMID: 17004249 Transplant Proc. 2007 Oct;39(8):2665-7 COMMUNICATIONS: Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005. A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007. POSTERS The Renal Association Annual Conference, May 2007, Brighton UK. "Indices of tolerance in kidney transplants" P103-PG05 American Transplant Congress May 2007, San Francisco USA. "Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients". American Transplant Congress May 2007, San Francisco USA. "Biomarkers of tolerance in kidney transplants". World Transplant Congress July 2006, Boston USA. "Advances in Immune Monitoring in Renal Transplantation". British Transplantation Society, March 2006, Edinburgh UK. "Indices of immunological tolerance". American Transplant Congress May 2007, San Francisco USA. "Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription". British Society of Immunology February 2007, Glasgow UK. "Tregs in peripheral blood of Clinically defined groups of renal transplant recipients" ORAL COMMUNICATIONS XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. "Indices of tolerance in kidney transplants." World Transplant Congress July 2006, Boston USA. "Indices of tolerance: Interim Report". 7th Trends in immunosuppression, February 2006 Berlin, Germany. "Fingerprinting tolerance in Renal Transplantation". Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21 American Transplant Congress May 2007. "Is it possible to tissue type a kidney donor who is no longer available?". 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. "T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection." Oral presentation by Patrick Miqueu.
 
Description Indices of Tolerance 
Organisation University of Oxford
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator. We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients
Collaborator Contribution Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did "the trans-vivo" DTH assay, etc ....
Impact JOURNAL ARTICLES: PMID: 20501946 PMID: 20501943 PMID: 20383145 PMID: 18633344 TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51 PMID: 17700166 PMID: 16082338 PMID: 17004249 Transplant Proc. 2007 Oct;39(8):2665-7 COMMUNICATIONS: Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005. A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007. POSTERS The Renal Association Annual Conference, May 2007, Brighton UK. "Indices of tolerance in kidney transplants" P103-PG05 American Transplant Congress May 2007, San Francisco USA. "Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients". American Transplant Congress May 2007, San Francisco USA. "Biomarkers of tolerance in kidney transplants". World Transplant Congress July 2006, Boston USA. "Advances in Immune Monitoring in Renal Transplantation". British Transplantation Society, March 2006, Edinburgh UK. "Indices of immunological tolerance". American Transplant Congress May 2007, San Francisco USA. "Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription". British Society of Immunology February 2007, Glasgow UK. "Tregs in peripheral blood of Clinically defined groups of renal transplant recipients" ORAL COMMUNICATIONS XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. "Indices of tolerance in kidney transplants." World Transplant Congress July 2006, Boston USA. "Indices of tolerance: Interim Report". 7th Trends in immunosuppression, February 2006 Berlin, Germany. "Fingerprinting tolerance in Renal Transplantation". Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21 American Transplant Congress May 2007. "Is it possible to tissue type a kidney donor who is no longer available?". 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. "T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection." Oral presentation by Patrick Miqueu.
 
Description Interdisciplinary Transplant Research Group 
Organisation University of Bristol
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution PI of group and grant holder for programme of research Increasing understanding on the quality and allocation of human organs for transplantation
Collaborator Contribution Contribution to group by workshop presentations, draft papers. The group is recently formed but outputs in the form of publications and policy document proposals are anticipated. Collaborators from the Universities of Cambridge, Oxford, and Bristol.
Impact Multidisciplinary: Law, Bioethics, Social Science, Clinical Science, Health Economics, Psychology.
Start Year 2013
 
Description Interdisciplinary Transplant Research Group 
Organisation University of Cambridge
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution PI of group and grant holder for programme of research Increasing understanding on the quality and allocation of human organs for transplantation
Collaborator Contribution Contribution to group by workshop presentations, draft papers. The group is recently formed but outputs in the form of publications and policy document proposals are anticipated. Collaborators from the Universities of Cambridge, Oxford, and Bristol.
Impact Multidisciplinary: Law, Bioethics, Social Science, Clinical Science, Health Economics, Psychology.
Start Year 2013
 
Description Interdisciplinary Transplant Research Group 
Organisation University of Oxford
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution PI of group and grant holder for programme of research Increasing understanding on the quality and allocation of human organs for transplantation
Collaborator Contribution Contribution to group by workshop presentations, draft papers. The group is recently formed but outputs in the form of publications and policy document proposals are anticipated. Collaborators from the Universities of Cambridge, Oxford, and Bristol.
Impact Multidisciplinary: Law, Bioethics, Social Science, Clinical Science, Health Economics, Psychology.
Start Year 2013
 
Description Ipierian 
Organisation Bristol-Myers Squibb
Department iPerian
Country United States of America 
Sector Private 
PI Contribution Tested the biological activity of antibody against the classical pathway of complement in an animal model.
Collaborator Contribution Provided the antibody and funding.
Impact showed the antibody (against human complement) was non functional in a rat model system.
Start Year 2013
 
Description Islet research group Dresden 
Organisation University of Dresden
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Sharing of human islet resources; collaborative grant application for trial of implantable device
Collaborator Contribution Our team provide human islets for research and we are about to start a King's based Diabetes UK funded study of implanting minimal islet mass in an immune isolating device in adults with type 1 diabetes as a pilot trial. £ 79020 has been awarded from Diabetes UK.
Impact 1st successful grant application
Start Year 2014
 
Description Jean-Paul Decuypere ERA-EDTA fellowship 
Organisation Catholic University of Louvain
Country Belgium, Kingdom of 
Sector Academic/University 
PI Contribution ongoing scientific collaboration, support by offering space ad facilities available for the research to be carried out and shared authorship of any publications that may arise form this collaboration; enabled fellow to obtain an ERA-EDTA fellowship.
Collaborator Contribution Bring expertise in autophagy tot he Centre and the ongoing research programme on Complement research.
Impact ERA-EDTA fellowship
Start Year 2014
 
Description Lecture tour of China 
Organisation Xi'an Jiaotong University
Department School of Medicine Xi'an Jiaotong
Country China, People's Republic of 
Sector Academic/University 
PI Contribution Lecturing to establish collaborations in research
Collaborator Contribution will be mutual cooperation on various projects
Impact None yet
Start Year 2013
 
Description Lecture tour of China 2 
Organisation School of Medicine
Department Respiratory Medicine
Country China, People's Republic of 
Sector Academic/University 
PI Contribution Hoping to gain collaborative partners in research
Collaborator Contribution Mutual cooperation in research projects
Impact none yet
Start Year 2013
 
Description Lombardi-Mullen 
Organisation King's College London (KCL)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution regulatory T cell expertise and models of skin transplantation
Collaborator Contribution expertise in full body imaging
Impact 2 publications already in pub med and 3 more in preparation
Start Year 2008
 
Description Lombardi-Nestle 
Organisation King's College London (KCL)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution regulatory T cell expertise and knowledge in the mechanisms of tolerance
Collaborator Contribution establishing in vivo model of human skin transplantation
Impact See publications - PubMed ID 22937164 & J.Exp.Med.209(5) 935-945; Ali et al. Plos ONE (In Press)
Start Year 2008
 
Description MABSOT Trial 
Organisation Opsona Therapeutics
Country Ireland, Republic of 
Sector Private 
PI Contribution Co-Chief investigator for the clinical trial. PI on work packages in animal, biomarker and Serum Amyloid A studies to support the trial.
Collaborator Contribution Provided the therapeutic agent, anti-TLR2 antibody. They also provided the contract work for analysis of biomarkers (with Almac).
Impact Drug manufacture. Completion of Phase 1 study in healthy volunteers. Identification of several potential biomarkers for ischaemia reperfusion injury of transplanted kidney. Clinical Trial recruitment started.
Start Year 2011
 
Description MRC Centre for Transplantation 
Organisation Medical Research Council (MRC)
Department MRC Centre for Transplantation
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Team has become emerged within the centre
Collaborator Contribution Increased collaboration with Richard Smith, Steve Sacks, Gio Lombardi and Maria Hernandez-Fuentes. All have had significant intellectual input into the work
Impact Being within the MRC Centre, within King's College London, within Guy's Hospital has significantly contributed to success in applications to British Heart Foundation, Kidney Research UK and commercial organisations for research funding.
Start Year 2009
 
Description Mark Thursz 
Organisation Imperial College Healthcare NHS Trust
Department Liver Department
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution supply of mice. delivery of a seminar, plus intellectual input into the
Collaborator Contribution began a new line of enquiry in a model of liver fibrosis, looking at the contribution of coagulation proteins
Impact Abstract at international meeting 2012
Start Year 2010
 
Description Mirococept collaboration with Cambridge University 
Organisation University of Cambridge
Department Veterinary School
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Supplied Mirococept and other reagents and collaborated in experiments.
Collaborator Contribution Providing laboratory facilities and Factor I
Impact Supportive data for clinical use of Mirococept in novel indications.
Start Year 2013
 
Description NIH Xenotransplantation at Pittsburgh 
Organisation University of Pittsburgh
Department Thomas E Starzl Transplantation Institute
Country United States of America 
Sector Academic/University 
PI Contribution Collaborator on NIH-funded Xenotransplantation programme. Latterly, advisor to renewed prgramme
Collaborator Contribution PhD student to work/train in my lab. Collaboration to supply membrane tethered hirulog (thrombalexin) 2013
Impact Multiple papers, reported elsewhere - 1st author Lin CC
Start Year 2006
 
Description Novartis 
Organisation Novartis
Department Transplantation & Immunology
Country Switzerland, Swiss Confederation 
Sector Private 
PI Contribution Two way sharing of data and techniques - including a trip to Basel in August 2011 to visit Novartis Global Research and to give a talk
Collaborator Contribution Financial assistance, technical help
Impact Paper in preparation.
Start Year 2011
 
Description OuTSMART investigators 
Organisation Barts Health NHS Trust
Department Royal London Renal Unit
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution All are co-applicants on OuTSMART grant
Collaborator Contribution Co-PIs at recruitment site
Impact None yet, except OuTSMART trial initiated and recruitment started.
Start Year 2013
 
Description OuTSMART investigators 
Organisation Central Manchester University Hospitals NHS Foundation Trust
Department Renal Care
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution All are co-applicants on OuTSMART grant
Collaborator Contribution Co-PIs at recruitment site
Impact None yet, except OuTSMART trial initiated and recruitment started.
Start Year 2013
 
Description OuTSMART investigators 
Organisation St James's University Hospital (Jimmy's)
Department Renal Unit
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution All are co-applicants on OuTSMART grant
Collaborator Contribution Co-PIs at recruitment site
Impact None yet, except OuTSMART trial initiated and recruitment started.
Start Year 2013
 
Description OuTSMART investigators 
Organisation University Hospitals Birmingham NHS Foundation Trust
Department Renal Department
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution All are co-applicants on OuTSMART grant
Collaborator Contribution Co-PIs at recruitment site
Impact None yet, except OuTSMART trial initiated and recruitment started.
Start Year 2013
 
Description Prof Andrew Cope (King's College London, UK) 
Organisation King's College London (KCL)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Assessment of the complement in aberrant T cell resposnes from rheumatoid arthritis (RA) patients
Collaborator Contribution Delivery of RA patient samples, collaborative experiments (the Cope and Kemper laboratory share a NovoNordisk-funded postdoctoral fellow, Dr. Esperanza perucha) and exchange od data and ideas
Impact Several high impact publications over the last 3 years, the last 'Evidence for intracellular C3 activation and its dysregulaion in autoimmune arthritis' which is currently in press. The data from this collaboration were presented at the 14th European meeting on Complement in Human Disease and chosen for an oral presentation and outstanding oral presentation award.
Start Year 2009
 
Description Prof David Abraham (UCL, UK) 
Organisation University College London (UCL)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Collaborative experiments, training of a postdoctoral fellow from Dr. Abraham's laboratory (Dr. Sandra Guerra) in T cell-related techniques with emphasis on the roles of CD46, C5L2 and CD109 in Scleroderma.
Collaborator Contribution Delivery of Scleroderma patients samples, collaborative experiments, exchange of data, reagents and ideas.
Impact We expect outputs and outcomes by the middle/end of 2014
Start Year 2013
 
Description Prof Joerg Koehl (University of Luebeck, Germany) 
Organisation University of Lübeck
Country Germany, Federal Republic of 
Sector Academic/University 
PI Contribution Collaborative experiments on new functions of C5aR and C5L2 in human T cell biology, exchange of ideas and data.
Collaborator Contribution Collaborative experiments, exchange of data and reagents. Delivery of commercially non-available key reagents.
Impact A manuscript is in preparation. The data from this collaboration were presented at the 14th European meeting on Complement in Human Disease and chosen for an oral presentation and outstanding oral presentation award.
Start Year 2010
 
Description Prof John Atkinson (Washington University in Saint Louis, USA) 
Organisation Washington University at St Louis
Country United States of America 
Sector Academic/University 
PI Contribution Collaborative experiments on the role of T cell-derived C3 in human Th1 biology, exchange of data and reagents
Collaborator Contribution Collaborative experiments on the role of T cell-derived C3 in human Th1 biology, exchange of data and reagents
Impact Publication currently in press ('Evidence for intracellular C3 activation and its dysregulaion in autoimmune arthritis') was performed in close collaboration with the Atkinson laboratory - this is reflected in the author contributions. The data from this collaboration were presented at the 14th European meeting on Complement in Human Disease and chosen for an oral presentation and outstanding oral presentation award.
Start Year 2009
 
Description Prof John Lambris (University of Pennsylvania, USA) 
Organisation University of Pennsylvania
Country United States of America 
Sector Academic/University 
PI Contribution Exchange of data on new functions of the C5aR and C5L2 in human T cell biology
Collaborator Contribution Delivery of specific, commercially non-available reagents, performance of experiments
Impact A manuscript is in preparation. The data from this collaboration were presented at the 14th European meeting on Complement in Human Disease and chosen for an oral presentation and outstanding oral presentation award.
Start Year 2012
 
Description Prof Masahide Takahashi (Nagoya University, Japan) 
Organisation Nagoya University
Country Japan 
Sector Academic/University 
PI Contribution Collaborative experiments on the role of CD109 in human T cell responses. We are assesing the novel function of CD109 mostly on human T cells.
Collaborator Contribution Dr. Takahashi's group provided the CD109 KO mouse strain to us and is performing at the same time experiments to asses the role of CD109n in vivo in infection models.
Impact Data generation is progressing well, we expect a first collaborative paper in 2014.
Start Year 2013
 
Description Prof Susan Lea (Oxford University, UK) 
Organisation University of Oxford
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Collaborative experiments on the role of the CD46/IL-2R crosstalk directing Th1 contraction, exchange of reagents, data and ideas.
Collaborator Contribution Collaborative experiments on the role of the CD46/IL-2R crosstalk directing Th1 contraction, exchange of reagents, data and ideas.
Impact High Impact publication in 2010. Next collaborative publication is expected in 2014.
Start Year 2010
 
Description Prof Tom Mollnes (Stockholm, Norway) 
Organisation University of Oslo
Country Norway, Kingdom of 
Sector Academic/University 
PI Contribution Collaborative experiments on new functions of C5aR and C5L2 in human T cell biology, exchange of ideas and data
Collaborator Contribution Delivery of rare C5-deficient patient samples, collaborative experiments, exchange of reagents
Impact A manuscript is in preparation. The data from this collaboration were presented at the 14th European meeting on Complement in Human Disease and chosen for an oral presentation and outstanding oral presentation award.
Start Year 2012
 
Description Pure Protein 
Organisation Pure Protein LLC
Country United States of America 
Sector Private 
PI Contribution Providing the samples and patient outcome data
Collaborator Contribution Biochemical expertise and availability of purified HLA proteins
Impact None yet - we are hoping to identify HLA-specific B cells
Start Year 2012
 
Description RISET - FP6 Consortium 
Organisation University Libre Bruxelles (Université Libre de Bruxelles ULB)
Country Belgium, Kingdom of 
Sector Academic/University 
PI Contribution Reprogramming the Immune System for Establishment of Tolerance. Validated the signature discovered in the Indices of Tolerance study.
Collaborator Contribution There were 15 partners that contributed to 7 workpackages in an integrated study.
Impact Multiple journal articles
 
Description Requirement of complement C3 for transplant tolerance induction 
Organisation King's College London (KCL)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Led to the initial observation that C3 deficient mice were resistant to tolerance induction.
Collaborator Contribution Provided a Clinical Fellow with an interest in complement and transplantation. This has enabled a new scientific question to be addressed.
Impact The initial results showing the requirement for C3 in tolerance to skin grafts was presented at an international meeting.
Start Year 2008
 
Description Retinoic acid in B cell function in the gut 
Organisation MRC Centre for Transplantation
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Developed models to study the role of retinoic acid in controlling B cell function
Collaborator Contribution Provided systems and technical expertise in analysis of B cell fatee
Impact none
Start Year 2012
 
Description Rigel Pharmaceuticals 
Organisation Rigel Pharmaceuticals
Country United States of America 
Sector Private 
PI Contribution We have developed a biomarker for clinical trial of the syk kinase inhibitor.
Collaborator Contribution Rigel has provided a new drug compound (syk kinase inhibitor)
Impact We have published a paper, Pubmed ID: 16946104
Start Year 2006
 
Description Role of CD39 in T-reg and Th17 plasticity 
Organisation Harvard Medical School
Department Beth Israel Deaconess Medical Center
Country United States of America 
Sector Hospitals 
PI Contribution Investigating the role of CD39 in shaping the balance between T-regs and Th17 cells in health, IBD and animal models of colitis
Collaborator Contribution Provided equipment, consumables and animals
Impact Nine peer-review papers (PMID: 22387392, 23787765, 23292173, 25042541, 25034284, 24681654, 22965858, 25172498 and 24505337) and six abstracts that have been accepted as oral presentations or posters at the Annual Meeting of the American Association of Immunologists (Boston, 4-8 May 2012), the European Congress of Immunology (Glasgow, 5-8 September 2012), the Digestive Disease Week (Orlando, 18-21 May 2013 and Chicago, 3-6 May 2014), the American Association for the Study of Liver Diseases (Boston, 9-13 November 2013). The poster presented at DDW in 2013 was awarded 'poster of distinction'.
Start Year 2010
 
Description Role of RA in GVHD 
Organisation University of Minnesota
Country United States of America 
Sector Academic/University 
PI Contribution Systems to stydy RA synthesis and signaling in the immune system
Collaborator Contribution Expertise in GVHD models
Impact NIH Grant R01 from 2012-2015
Start Year 2012
 
Description Royal Society of Edinburgh 
Organisation Royal Society of Edinburgh (RSE)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Learned Society 
PI Contribution Oral presentation and contribution to expert working group on organ donation
Collaborator Contribution Application and submission and award of RS Edin grant
Impact Multidisciplinary - Applied Philosophy, Health Law, Bioethics, Medicine
Start Year 2013
 
Description STIFF FLOP 
Organisation European Commission (EC)
Country European Union (EU) 
Sector Public 
PI Contribution Design, development and validation of an octopus inspired soft robot
Collaborator Contribution ?
Impact 200 publications, over 30 presnetations in international meetings, IEEE workshops, press coverageby the BBC, MULTIDICIPLINARY COLLABORATION between engineers,computer scientists,simulation experts and surgeons
Start Year 2012
 
Description Sanger Centre 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution Development of collaborative programme
Collaborator Contribution Development of collaborative programme
Impact Publications from Prof Adrian Hayday. Journal of Investigative Dermatology 2009 (eprint ahead of publication). European Journal of Immunology 39: 1794-1806. Study of human gamma delta T-cell subsets and functions.
Start Year 2007
 
Description Structural Studies on VISTA in the mouse 
Organisation Yeshiva University
Department Albert Einstein College of Medicine
Country United States of America 
Sector Academic/University 
PI Contribution Provision of construcrts of VISTA to study VISTA structure
Collaborator Contribution Expert structural biologist to study structure function relationships
Impact NIH grant R01 from 2011-2016
Start Year 2011
 
Description Studies on collectin 11 in renal ischaemia-reperfusion injury 
Organisation University of Leicester
Department Department of Infection Inflammation and Immunity
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution We are the principle investigators on a grant that funds this research. This includes animal models for native and transplanted kidneys and cell culture studies
Collaborator Contribution Expertise on the lectin pathway.
Impact Journal of Clinical Investigation publication in press.
Start Year 2015
 
Description Studies on the antagonism of CD59 as an anti-tumour strategy 
Organisation Imperial College London (ICL)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution This project concerns the cytotopic modification of a peptide antagonist of CD59. My group has provided recombinant human CD59 in both cytotopic and unmodified forms. We have also provided a cytotopic reagent to permit the modification of the antagonist.
Collaborator Contribution Our partners have undertaken structural studies on CD59 and modified CD59 binding to liposomes as a model for cellular interaction.
Impact Part of the structural work has been published in 2013
Start Year 2012
 
Description Suppression of kidney disease by VISTA-Ig 
Organisation MRC Centre for Transplantation
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Developed VISTA-Ig as an immunosuppressive drug
Collaborator Contribution Developed murine models of kidney disease to test VISTA-Ig
Impact none
Start Year 2013
 
Description The KCL-Belgium-China herbal toxicity axis 
Organisation University Libre Bruxelles (Université Libre de Bruxelles ULB)
Country Belgium, Kingdom of 
Sector Academic/University 
PI Contribution I led the conception, research design and oversaw the whole project.
Collaborator Contribution Qu is a visiting fellow in my lab, who brought in knowledge and resources on Chinese herbal medicine and drafted the part of information published in Chinese; Bunel was a PhD studewnt of Duez, who led the first draft, esp. focused on those information published in English; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez and Qu are Co-Chairs of the Pharmacology & Toxicology Interest Group of the GP-TCM Research Association that I led to establish in 2012.
Impact This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&flag=1&journal_id=sjzyyw&year_id=2015 (2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075 http://www.sciencemag.org/content/347/6219/337.3.summary (3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075 http://www.sciencemag.org/content/346/6216/1569.4.summary
Start Year 2007
 
Description The KCL-Belgium-China herbal toxicity axis 
Organisation University of Mons
Country Belgium, Kingdom of 
Sector Academic/University 
PI Contribution I led the conception, research design and oversaw the whole project.
Collaborator Contribution Qu is a visiting fellow in my lab, who brought in knowledge and resources on Chinese herbal medicine and drafted the part of information published in Chinese; Bunel was a PhD studewnt of Duez, who led the first draft, esp. focused on those information published in English; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez and Qu are Co-Chairs of the Pharmacology & Toxicology Interest Group of the GP-TCM Research Association that I led to establish in 2012.
Impact This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&flag=1&journal_id=sjzyyw&year_id=2015 (2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075 http://www.sciencemag.org/content/347/6219/337.3.summary (3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075 http://www.sciencemag.org/content/346/6216/1569.4.summary
Start Year 2007
 
Description The KCL-Belgium-China herbal toxicity axis 
Organisation Zhejiang University
Country China, People's Republic of 
Sector Academic/University 
PI Contribution I led the conception, research design and oversaw the whole project.
Collaborator Contribution Qu is a visiting fellow in my lab, who brought in knowledge and resources on Chinese herbal medicine and drafted the part of information published in Chinese; Bunel was a PhD studewnt of Duez, who led the first draft, esp. focused on those information published in English; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez and Qu are Co-Chairs of the Pharmacology & Toxicology Interest Group of the GP-TCM Research Association that I led to establish in 2012.
Impact This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&flag=1&journal_id=sjzyyw&year_id=2015 (2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075 http://www.sciencemag.org/content/347/6219/337.3.summary (3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075 http://www.sciencemag.org/content/346/6216/1569.4.summary
Start Year 2007
 
Description The KCL-Belgium-HKU herbal fibrosis axis 
Organisation University of Hong Kong
Country Hong Kong, Special Administrative Region of China 
Sector Academic/University 
PI Contribution I led the conception, research design and oversaw the whole project.
Collaborator Contribution Feng brought in knowledge and resources on Chinese herbal medicine; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez, as well as King's academic co-authors Hendry and Hylands are members of the GP-TCM Research Association that I led to establish in 2012.
Impact This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&flag=1&journal_id=sjzyyw&year_id=2015 (2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075 http://www.sciencemag.org/content/347/6219/337.3.summary (3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075 http://www.sciencemag.org/content/346/6216/1569.4.summary
Start Year 2007
 
Description The KCL-Belgium-HKU herbal fibrosis axis 
Organisation University of Mons
Country Belgium, Kingdom of 
Sector Academic/University 
PI Contribution I led the conception, research design and oversaw the whole project.
Collaborator Contribution Feng brought in knowledge and resources on Chinese herbal medicine; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez, as well as King's academic co-authors Hendry and Hylands are members of the GP-TCM Research Association that I led to establish in 2012.
Impact This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&flag=1&journal_id=sjzyyw&year_id=2015 (2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, Stévigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075 http://www.sciencemag.org/content/347/6219/337.3.summary (3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075 http://www.sciencemag.org/content/346/6216/1569.4.summary
Start Year 2007
 
Description The role of VISTA in inflammatory bowel disease 
Organisation MRC Centre for Transplantation
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Showed that VISTA was expressed in the gut
Collaborator Contribution Developed systems to test the role of VISTA in murine models of IBD
Impact AICR grant from 2012-2015
Start Year 2012
 
Description The role of retinioic acid in regulatory t cell function 
Organisation MRC Centre for Transplantation
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Defined that regulatory T cells need retinoic acid to function
Collaborator Contribution Defined the role in human regulatory T cells
Impact None
Start Year 2012
 
Description The role of the lactin pathway (MASP2) in ischemia reperfusion injury 
Organisation University of Leicester
Department Department of Infection Inflammation and Immunity
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Models for ischemia reperfusion injury in native and transplant organs using knockout mice.
Collaborator Contribution Revised my thinking on the complement pathway responsible for triggering complement activation during and after transplantation
Impact Presentation at International complement and transplant meetings Publication in PNAS; second publication submitted Collaboration with industry (OMEROS) on a new theraputic monoclonal antibody
Start Year 2006
 
Description Therapeutic strategy for toll like receptor blockade in ischaemia reperfusion injury of kidney transplant 
Organisation Opsona Therapeutics
Country Ireland, Republic of 
Sector Private 
PI Contribution Senior PI at the Centre is the chief clinical investigator and leads work packages on biomarker identification and pre-clinical models using therapeutic antibody.
Collaborator Contribution by providing therapeutic tools their contribution has enhanced our understanding of the role of the innate immune response in transplantation and the interaction between toll like receptors and complementby providing therapeutic tools their contribution has enhanced our understanding of the role of the innate immune response in transplantation and the interaction between toll like receptors and complement
Impact Publication in FASEBJ concerning the pre-clinical results
Start Year 2008
 
Description Therapeutic strategy for toll like receptor blockade in ischaemia reperfusion injury of kidney transplant 
Organisation University of Dublin
Department Trinity College Dublin
Country Ireland, Republic of 
Sector Academic/University 
PI Contribution Senior PI at the Centre is the chief clinical investigator and leads work packages on biomarker identification and pre-clinical models using therapeutic antibody.
Collaborator Contribution by providing therapeutic tools their contribution has enhanced our understanding of the role of the innate immune response in transplantation and the interaction between toll like receptors and complementby providing therapeutic tools their contribution has enhanced our understanding of the role of the innate immune response in transplantation and the interaction between toll like receptors and complement
Impact Publication in FASEBJ concerning the pre-clinical results
Start Year 2008
 
Description Tolerance in Renal Transplantation 
Organisation Guy's and St Thomas' NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution I have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved